Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis
NCT06431750 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2025-01-14
Summary
This is a multicenter, non-interventional, cohort study in pediatric patients with active juvenile enthesitis-related or psoriatic arthritis
Conditions
- Juvenile Idiopathic Arthritis
Interventions
- OTHER
-
Secukinumab
This is an observational study, there is no treatment allocation.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 6 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-30
- Primary Completion
- 2028-08-30
- Completion
- 2028-08-30
More Related Trials
-
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
NCT04209205 ·Status: COMPLETED ·Phase: PHASE3
-
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
NCT07243782 ·Status: RECRUITING
-
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
NCT01989468 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
NCT02745080 ·Status: COMPLETED ·Phase: PHASE3
-
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
NCT02471144 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
NCT03066609 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
NCT02698475 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
NCT01365455 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
NCT01952015 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Secukinumab in Mild Psoriasis
NCT03131570 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551 ·Status: RECRUITING ·Phase: PHASE3
-
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
NCT01892436 ·Status: COMPLETED ·Phase: PHASE3
-
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
NCT05215561 ·Status: COMPLETED
-
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
NCT01555125 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
NCT01412944 ·Status: COMPLETED ·Phase: PHASE3
-
Plaque Psoriasis Efficacy and Safety With Secukinumab
NCT02409667 ·Status: COMPLETED ·Phase: PHASE3
-
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
NCT05388916 ·Status: COMPLETED
-
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
NCT02595970 ·Status: COMPLETED ·Phase: PHASE3
-
Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
NCT02008890 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Secukinumab With 2 mL Pre-filled Syringes
NCT02748863 ·Status: COMPLETED ·Phase: PHASE3
-
Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment
NCT06666114 ·Status: COMPLETED
-
Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.
NCT01900782 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
NCT01806597 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Secukinumab in the Treatment of Psoriatic Arthritis
NCT02854163 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
NCT04632927 ·Status: COMPLETED ·Phase: PHASE3